Pragati Healthcare

Daryaganj, Delhi

• MOQ 3 Pack(s)
• Disease NameHepatitis C

Sofosbuvir (brand name Sovaldi) is a new medication used to treat hepatitis C. It was approved in Europe in January 2014 for treatment of adults with all genotypes of chronic hepatitis C. For some people, sofosbuvir will be the first interferon-free hepatitis C treatment option. For others, sofosbuvir can greatly shorten treatment when added to pegylated interferon and ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant.

• MOQ 3 Box
• Disease NameHepatitis C

Natdac or Daclatasvir (brand name Daklinza) is a new medication used to treat hepatitis C. It was approved in Europe in January 2014 for treatment of adults with all genotypes of chronic hepatitis C. For some people, sofosbuvir will be the first interferon-free hepatitis C treatment option. For others, sofosbuvir can greatly shorten treatment when added to pegylated interferon and ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant. Contact us - exports@pragatihc.com

• MOQ 3 Box
• Disease NameHepatitis C

Natco Hepcinat LP (Ledipasvir + Sofosbuvir) - Harvoni is a new medication used to treat hepatitis C. It is a combination pill containing sofosbuvir (sold separately as Sovaldi) plus ledipasvir. It was approved in Europe in November 2014 for treatment of adults with genotype 1 or 4 chronic hepatitis C, and for some people with genotype 3. For many people with these genotypes, Harvoni is an interferon-free and ribavirin-free hepatitis C treatment option. Some people with harder-to-treat disease may do better if they add ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis C such as liver cancer or needing a liver transplant.

• MOQ 3 Box
• Disease NameHepatitis C

Velpanat (sofosbuvir + velpatasvir) - epclusa is a new medication used to treat hepatitis c. It is a combination pill containing sofosbuvir (sold separately as sovaldi) plus velpatasvir. It was approved in europe in july 2016 for treatment of adults with all genotypes (1, 2, 3, 4, 5 and 6) of chronic hepatitis c. Epclusa is the first pangenotypic interferon-free hepatitis c treatment regimen, meaning it works against all hepatitis c genotypes. It is more effective than the older harvoni combination (sofosbuvir + ledipasvir) for people with genotype 3. Some people with harder-to-treat disease may do better if they take epclusa with ribavirin. Successful treatment reduces the risk of long-term complications of hepatitis c such as liver cancer or needing a liver transplant.

• MOQ 3 Pack(s)

Generic Name-Carmustine, Marketed By-Emcure Pharmaceuticals Ltd, Pack Size-1 Injection, Primary Use-Brain Tumor

• MOQ 3 Pack(s)

Generic Name-Oxaliplatin, Marketed By-Cipla Ltd, Pack Size-1 Injection, Primary Use-Colon Cancer

We have a good basket of fast-moving specialty products available for product registration in your region for your exclusive marketing. Our partner manufacturing facilities are USFDA/EMEA/PICs/WHO-GMP certified. We provide dossiers for product registration. Our range includes specialty products of Oncology, Nephrology , HIV, Hepatitis, and other specialty segments.